Home » 제품 » Ready-to-Use NGS Panel » Liquid Biopsy
Circulating Tumor DNA Panel – Colorectal / Lung / Breast
Discover the accelerated NGS with Reliable result for variant with ultra low VAF
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Revolutionary Bioinformatics solution providing fast and
accurate, client-specific analysis services.
Trust CAS with your BI analysis !
Highly optimized library preparation kit to be used with all Celemics ready-to-use or customized panels. Experience the incomparable efficiency and performance for NGS library preparation
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Celemics’ comprehensive NGS panel for somatic cancer allows highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors.
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >Utilizing NGS-based target enrichment methods for higher genotyping efficiency and accuracy. Providing cost-effective and optimized experiment compared to conventional methods, such as GBS, PCR and microarray in plant and animal research
View Detail >Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >Find useful information, insights and tools for your Celemics’ products and services
View Detail >In-silico designed and wet-lab validated exclusive probes to ensure state-of-the-art capture performance
View Detail >Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >Let’s change the NGS market together – our global presence and partners world-wide
View Detail >Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Discover the accelerated NGS with Reliable result for variant with ultra low VAF
ctDNA를 이용한 연구는 미량의 샘플에서 낮은 빈도로 발생하는 변이를 검출할 수 있는 높은 민감도가 필수적으로 요구됩니다.
셀레믹스의 ctDNA 패널은 서울대학교와의 협업으로 2017년부터 개발된 패널입니다. Colon, Lung, Breast Cancer의 3종의 암과 연관되어 있는 것으로 알려진 다수의 유전자들을 분석할 수 있으며, 미량의 샘플에서도 충분한 분석 능력을 얻기 위해 프로브 디자인 기술, 시퀀싱 노이즈 제거, 시약 최적화 등 셀레믹스의 독자적인 기술을 모두 담았습니다. 임상 수준에서 검증 완료한 최적화된 패널을 공급해 드립니다.
아래는 서울대학교 병원에서 실제 임상 샘플을 이용해 검증 실험한 자료입니다. 분석 유전자 리스트는 광범위한 검증 실험을 통해 확정되었습니다. 최종적으로 16 개의 유전자가 Colorectal Cancer 패널에 포함되어 있으며, Breast Cancer 패널에는 14개 유전자, Lung Cancer 패널에는 15개의 유전자가 포함되어 있습니다.
미량의 샘플에 포함된 유전 변이를 정확히 분석하기 위해 셀레믹스는 독자적인 UMI 알고리즘을 사용합니다. 효과적으로 Duplication Read들을 제거하고 신뢰도 높은 Consensus Read 생성을 위해 개발한 분석 소프트웨어는 높은 품질의 데이터 분석 결과를 고객에 제공합니다.
자체 설계된 모듈식 소프트웨어를 통해 Raw Data에서 Clinical Interpretation 리포트에 이르기까지 고객이 원하는 수준의 결과를 제공합니다.
실제 임상에서 얻은 샘플을 통해 민감도와 특이도 테스트를 마친 제품을 공급합니다. 10 ng 정도의 적은 양으로도 NGS 실험을 진행할 수 있습니다.
이미 많은 연구자들이 본 패널과 함께 연구를 진행하고 있으며, 그동안 발간된 많은 논문들이 본 패널의 우수성을 이야기해 줍니다.
셀레믹스에서는 시퀀싱 에러 및 노이즈 제거를 위한 독자적인 알고리즘을 개발하였습니다. 보다 정확하고 신뢰성 높은 결과를 고객에 제공합니다.
본 기술은 지속적인 모니터링을 통해 지금도 개선되고 있는 중이며, 보다 정확도 높은 결과를 제공해 드리기 위한 셀레믹스의 지식 산물입니다.
Colorectal Cancer | Breast Cancer | Lung Cancer | |
---|---|---|---|
Gene count* | 16 genes | 27 genes | 28 genes |
Covered region | Whole CDS | ||
Target size | 18 kb | 99 kb | 47 kb |
Mutation type | SNV, Indel | ||
Sample type (amount) | Plasma (>20 ng of cfDNA) | ||
Platform | All sequencers from illumina and MGI | ||
Bioinformatics pipeline |
1. Primary and Secondary analysis result (FASTQ to VCF) 2. Secondary Analysis: CNV, Large InDel 3. Tertiary Analysis: Clinical interpretation * Linux-based consensus read generation software |
ctDNA Colorectal Cancer Panel | APC | BRAF | EGFR | ERBB2 | ERBB3 | FGFR1 | HRAS | IRS1 |
---|---|---|---|---|---|---|---|---|
KRAS | MAP2K1 | MET | NRAS | PDGFRB | PIK3CA | PTEN | TP53 |
ctDNA Breast Cancer Panel |
AKT1 | APC | AR | BRCA1 | BRCA2 | CCND1 | CDH1 | EGFR |
---|---|---|---|---|---|---|---|---|
ERBB2 | ESR1 | FGFR1 | FGFR2 | GATA3 | IGF1R | KIT | KRAS | |
MAP2K4 | MAP3K1 | MDM2 | MYC | NF1 | PIK3CA | PIK3R1 | PTEN | |
RB1 | TOP2A | TP53 |
ctDNA Lung Cancer Panel |
AKT1 | ALK | ARAF | ARID1A | BRAF | CBL | CDKN2A | EGFR |
---|---|---|---|---|---|---|---|---|
ERBB2 | HRAS | KEAP1 | KRAS | MAP2K1 | MET | MTOR | NF1 | |
NRAS | NTRK1 | NTRK2 | PIK3CA | PTEN | RB1 | RIT1 | ROS1 | |
SETD2 | STK11 | TP53 | U2AF1 |
NGS Library Preparation 키트로 셀레믹스의 Target Enrichment 패널에 최적화된 키트
셀레믹스에서 제공하는 BI 분석 서비스로 다양한 수준의 분석 결과 제공 가능
최고 품질의 마그네틱 비드로 사용하기 편리하며 높은 재현성을 보여 NGS 실험에 최적화된 비드
PCR 반응에 필요한 모든 구성요소를 포함하고 있는 믹스 제품이며 NGS에서 요구하는 정확도를 충족한 제품
Technical Resources
[Product Overview] Circulating Tumor DNA Panel (Colorectal, Breast, Lung)
[Product Overview] Celemics Target Enrichment Panel Overview
[Catalogue] Celemics Products & Service Catalogue_All Products & Service
Safety Data Sheets
MSDS_Liquid Biopsy Panel_Illumina_Enzymeplus
MSDS_Liquid Biopsy Panel_Illumina
MSDS_Liquid Biopsy Panel_Thermo Fisher
MSDS_Liquid Biopsy Panel_MGI_EnzymePlus
MSDS_Liquid Biopsy Panel_MGI
Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.
10.2217/epi-2021-0477
So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.
DOI 10.4111/icu.20220044
Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.
DOI 10.1038/s41598-022-05931-3
Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.
DOI 10.1186/s12920-022-01191-2